Patents by Inventor Alain Lacampagne

Alain Lacampagne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9987327
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: June 5, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSITANCE PUBLIQUE—HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE, UNIVERSITE D'ANGERS
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • Publication number: 20170049854
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Application
    Filed: October 17, 2016
    Publication date: February 23, 2017
    Inventors: Alain LACAMPAGNE, Jerome THIREAU, Olivier CAZORLA, Jean-Yves LE GUENNEC, Jeremy FAUCONNIER, Maria del Carmen MARTINEZ, Ramaroson ANDRIANTSITOHAINA, Bijan GHALEH-MARZBAN, Raffaella SOLETI
  • Patent number: 9504732
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Grant
    Filed: January 14, 2014
    Date of Patent: November 29, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE MONTPELLIER, ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS, UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
    Inventors: Alain Lacampagne, Jerome Thireau, Olivier Cazorla, Jean-Yves Le Guennec, Jeremy Fauconnier, Maria del Carmen Martinez, Ramaroson Andriantsitohaina, Bijan Ghaleh-Marzban, Raffaella Soleti
  • Publication number: 20150352182
    Abstract: The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction.
    Type: Application
    Filed: January 14, 2014
    Publication date: December 10, 2015
    Inventors: Alain LACAMPAGNE, Jerome THIREAU, Olivier CAZORLA, Jean-Yves LE GUENNEC, Jeremy FAUCONNIER, Maria del Carmen MARTINEZ, Ramaroson ANDRIANTSITOHAINA, Bijan GHALEH-MARZBAN, Raffaella SOLETI
  • Publication number: 20100184703
    Abstract: The inventors have studied the kinetic and hierarchy of activation of apoptogenic caspases during myocardial ischemia and have found that caspase 2 plays a major role during the cardiac pathology by a very fast activation after an ischemic episode. Experiments were carried out on animal models of transitory or permanent myocardial ischemia. It was then observed that electrophysiological remodeling and post-ischemic fibrosis were prevented by using caspase-2 specific inhibitors. The invention is then based on the demonstration that caspase-2 and its activation represents an early and transitory step of the cardiac apoptotic mechanisms resulting from a myocardial ischemic and involved in the development of hypertrophy and cardiac insufficiency. The invention thus relates to a method of treatment of cardiovascular pathologies resulting from ischemia by using certain caspase-2 specific inhibitors.
    Type: Application
    Filed: June 27, 2008
    Publication date: July 22, 2010
    Applicants: CHIESI FARMACEUTICI S.p.A., INST. NAT. DE LA SANTE ET DE LA RECH. MED.(INSERM)
    Inventors: Richard Casimir, David Chauvier, Etienne Jacotot, Alain Lacampagne, Jeremy Fauconnier